{"id":603506,"date":"2009-10-23T13:48:19","date_gmt":"2009-10-23T17:48:19","guid":{"rendered":"tag:www.hepatitis-central.com,2009:\/mt\/\/1.717"},"modified":"2009-10-23T13:50:30","modified_gmt":"2009-10-23T17:50:30","slug":"hcv-trial-begins-for-new-immune-drug","status":"publish","type":"post","link":"https:\/\/mereja.com\/index\/603506","title":{"rendered":"HCV Trial Begins for New Immune Drug"},"content":{"rendered":"<p>SciClone begins a Phase II trial to evaluate how a new drug designed to stimulate the immune system fares against Hepatitis C.<\/p>\n<p>SciClone starts hepatitis C drug trial<\/p>\n<p>Wednesday, October 21, 2009<\/p>\n<p>SciClone Pharmaceuticals Inc. enrolled the first patient in a mid-stage test of a hepatitis C treatment.<\/p>\n<p>Foster City-based SciClone (NASDAQ: SCLN) signed up the patient in Atlanta to test SCV-07, a small molecule that stimulates the immune system. In this Phase II trial it&#8217;s being tested alone or in combination with ribavirin, another drug.<\/p>\n<p>Read the entire article:<br \/>\n<a href=\"http:\/\/sanfrancisco.bizjournals.com\/sanfrancisco\/stories\/2009\/10\/19\/daily47.html\">http:\/\/sanfrancisco.bizjournals.com\/sanfrancisco\/stories\/2009\/10\/19\/daily47.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SciClone begins a Phase II trial to evaluate how a new drug designed to stimulate the immune system fares against Hepatitis C. SciClone starts hepatitis C drug trial Wednesday, October 21, 2009 SciClone Pharmaceuticals Inc. enrolled the first patient in a mid-stage test of a hepatitis C treatment. Foster City-based SciClone (NASDAQ: SCLN) signed up [&hellip;]<\/p>\n","protected":false},"author":288,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4821],"tags":[],"class_list":["post-603506","post","type-post","status-publish","format-standard","hentry","category-news"],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p9NivD-2wZY","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/603506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/users\/288"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/comments?post=603506"}],"version-history":[{"count":0,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/603506\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/media?parent=603506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/categories?post=603506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/tags?post=603506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}